Skip to content

Regenxbio RGNX Short- term Investments

Short- term Investments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
Roivant Sciences logo
Roivant SciencesROIV
Sutro Biopharma logo
Sutro BiopharmaSTRO

Other financials

Income statement

See full
Revenue$6.4M-92.8%
Gross profit$14.9M+35.7%
Operating income-$83.4M-787%
Net income-$90.1M-1,580%
EPS (diluted)-$1.72-1,533%

Balance sheet

See full
Cash & equivalents$15.2M-88.3%
Total debt$71.1M-11.0%
Total equity$21.1M-92.3%
Total assets$341.9M-30.4%

Cash flow

See full
Operating cash flow-$76.2M-327%
CapEx$1.2M+20.6%
Free cash flow-$77.4M-337%

Valuation

See full
Market cap$529.38M+24.6%
Enterprise value$585.22M+56.3%
P/S+3.3×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-292.3%-613pp
Net margin-330.2%-588pp
FCF margin-269.2%-364pp

Returns & leverage

See full
Return on equity-196.4%-288pp
Debt / equity3.4×+3.1×
Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regenxbio's short- term investments?
Regenxbio (RGNX) reported short- term investments of $135.26M in Q1 2026.
How has Regenxbio's short- term investments changed year-over-year?
Regenxbio's short- term investments decreased by 1.8% year-over-year, from $137.77M to $135.26M.
What is the long-term trend for Regenxbio's short- term investments?
Over 5 years (2020 to 2025), Regenxbio's short- term investments has grown at a 7.3% compound annual growth rate (CAGR), from $137.31M to $195.6M.